OTLC
insider transactionsOncotelic Therapeutics, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 30d
+335.8K
335.8K buy · 0 sell
Net value · 30d
$15.0K
$15.0K in · $0 out
Sentiment · 30d
Net buying
100% buying · 0% selling
Open-market trades · 30d
2
335.8K buy · 0 sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Buy·P
Vuong Trieu KEY
CHAIRMAN AND CEO
$10.7K
239.8K sh · $0.04
Own +0%
-
Buy·P
Vuong Trieu KEY
CHAIRMAN AND CEO
$4.3K
96.0K sh · $0.05
Own +0%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 17, 2026 | Vuong Trieu KEY | Buy P | 239.8K | $10.7K |
| Jun 15, 2026 | Vuong Trieu KEY | Buy P | 96.0K | $4.3K |
About OTLC insider trading
This page tracks insider transactions for Oncotelic Therapeutics, Inc. (OTLC) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.